Grund Nicholas
SEC insider (Form 3/4/5 filer). CIK 0001661887. Chief Commercial Officer at Akebia Therapeutics, Inc. (AKBA). 5 reported Form 4/5 transactions since Sep 2024; latest on Feb 2, 2026. Located in CAMBRIDGE, MA.
Companies Grund Nicholas has filed insider reports for
- Akebia Therapeutics, Inc. (AKBA): Officer, Chief Commercial Officer
Grund Nicholas
CIK: 0001661887
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)3 (60.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)2 (40.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
AKBA
Akebia Therapeutics, Inc.
Officer
Discretionary Trading P&L
Holdings
Transaction History (5 total)
- Feb 2, 2026AKBA
Akebia Therapeutics, Inc.
SaleDirect53.6K shares at avg. $1.39$74K - Feb 2, 2026AKBA
Akebia Therapeutics, Inc.
SaleDirect31.2K shares at avg. $1.39$43K - Jan 30, 2026AKBA
Akebia Therapeutics, Inc.
AwardDirect204K shares- - Feb 3, 2025AKBA
Akebia Therapeutics, Inc.
SaleDirect55.6K shares at avg. $2.10$117K - Jan 31, 2025AKBA
Akebia Therapeutics, Inc.
AwardDirect194.9K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Feb 2, 2026 | AKBA Akebia Therapeutics, Inc. | Sale | 53,585 | $1.39 | $74,483 | Direct |
| Feb 2, 2026 | AKBA Akebia Therapeutics, Inc. | Sale | 31,244 | $1.39 | $43,429 | Direct |
| Jan 30, 2026 | AKBA Akebia Therapeutics, Inc. | Award | 204,000 | - | $0 | Direct |
| Feb 3, 2025 | AKBA Akebia Therapeutics, Inc. | Sale | 55,621 | $2.10 | $116,804 | Direct |
| Jan 31, 2025 | AKBA Akebia Therapeutics, Inc. | Award | 194,900 | - | - | Direct |
1-5 of 5 transactions